2022
DOI: 10.1101/2022.12.07.519433
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Dalpiciclib Partially Abrogates ER Signaling Activation Induced by Pyrotinib In HER2+HR+Breast Cancer

Abstract: Background: Recent evidences from clinical trials (NCT04486911) revealed that the combination of pyrotinib, letrozole and dalpiciclib exerted optimistic therapeutic effect to treat HER2+HR+ breast cancer, however, the underlying molecular mechanism remained further investigation. Methods: Through the drug sensitivity test, the drug combination efficacy of pyrotinib, tamoxifen and dalpiciclib to BT474 cells were tested. The underlying molecular mechanisms were investigated using immunofluorescence, western blot… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 28 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?